Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia